Leukemia, B-cell
Conditions
Keywords
γδT, leukemia
Brief summary
Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Detailed description
γδT cells belong to the innate immune system and have a powerful anti-tumor effect. Leukemia patients transplanted with allogeneic hematopoietic stem cells have an important role in controlling leukemia recurrence. Although adoptive immunotherapy using in vitro expanded γδT cells has achieved significant results in patients with solid tumors, infusion of donor γδT cells in leukemia patients undergoing allogeneic hematopoietic stem cell transplantation to prevent leukemia recurrence has not been reported. . This clinical study intends to initially observe the safety and effectiveness of donor γδT cell infusion to prevent recurrence/refractory leukemia salvage allogeneic hematopoietic stem cell transplantation to further improve the transplantation effect of these patients
Interventions
DRUGγδT Cell infusion agent
γδT
Sponsors
The First Affiliated Hospital of Soochow University
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
10 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Acute leukemia patients undergoing salvage allogeneic hematopoietic stem cell transplantation * Age 10-65,Any gender * Expected lifetime\>3months * ECOG 0-2 * DSA Negative * Successful granulocyte implantation * Liver and kidney function, heart and lung function meet the following requirements:①Creatinine≤1.5 ULN；②ALT/AST ≤5 ULN； ③Baseline oxygen saturation≥92%； ④Left ventricular ejection fraction≥50% * Female subjects with fertility who had a negative pregnancy test within 48 hours before the infusion and were not breastfeeding; all subjects with fertility potential before enrolling in the study and throughout the study period until the last infusion Within 3 months, take adequate contraceptive measures * Signing informed consent patients must be able to understand and be willing to participate in this study, and sign informed consent at the same time
Exclusion criteria
* Donor HBsAg or HBcAb positive and HBV DNA titer test is not within the normal reference value; donor or patient HCV antibody positive and peripheral blood HCV RNA positive; donor or patient HIV antibody positive; donor syphilis test positive * Active central nervous system disease * BMI index\>35 * Allergic to DMSO * Graft-versus-host disease * Septic shock * Systemic steroid therapy is required during cell infusion or cell collection, or there are conditions that researchers believe may require steroid therapy during blood collection or during infusion. In addition to cell collection or infusion, steroids for disease treatment are allowed, and inhaled steroids or hydrocortisone are also allowed for physiological replacement therapy in patients with adrenal insufficiency * Participated in another clinical trial within 4 weeks before enrolling in the study, or intend to participate in another clinical trial throughout the study * According to the judgment of the investigator, it does not meet the situation of cell preparation * Circumstances considered by other researchers to be inappropriate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identification of the dose limiting toxicity (DLT) | 4 weeks after γδT infusion | Toxicity will be assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) scale, version 5 and the number of patients experiencing DLT will be evaluated. |
| The incidence of serious adverse events (SAEs) | 4 weeks after γδT infusion | The incidence of serious adverse events (SAEs) after γδT infusion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival time(DFS) | about 2 years after γδT infusion | γδT cell infusion treatment of CR/CRi patients from the beginning of γδT cell infusion treatment to the first disease recurrence or death from any cause |
| Overall survival (OS) | about 2 years after γδT infusion | The time from the subject receiving γδT cell infusion treatment to death (for any reason) |
| Duration of remission after administration (DOR) | about 2 years after γδT infusion | γδT cell infusion treatment has not reached CR/CRi before the treatment, the time from the first assessment of CR/CRi after administration to the first assessment of disease recurrence or progression or death from any cause |
Countries
China
Contacts
Primary ContactSuning Chen, Ph.D
Backup ContactXiaofei Yang, Ph.D
Outcome results
None listed